The Interleukin-17 G-197A Polymorphism is Associated with Cyclosporine Metabolism and Transplant Rejection in Liver Transplant Recipients

References

• Martin P , DimartiniA , FengS , BrownRJr , FallonM . Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation . Hepatology59 ( 3 ), 1144 – 1165 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Heimbach JK , HiroseR , StockPGet al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States . Hepatology61 ( 5 ), 1643 – 1650 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Dutkowski P , LineckerM , DeoliveiraML , MullhauptB , ClavienPA . Challenges to liver transplantation and strategies to improve outcomes . Gastroenterology148 ( 2 ), 307 – 323 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Asrani SK . Liver transplantation for nonalcoholic steatohepatitis . Clin. Gastroenterol. Hepatol.12 ( 3 ), 403 – 404 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dienstag JL , CosimiAB . Liver transplantation – a vision realized . N. Engl. J. Med.367 ( 16 ), 1483 – 1485 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Peralvarez M , De La MataM , BurroughsAK . Liver transplantation: immunosuppression and oncology . Curr. Opin. Organ Tran.19 ( 3 ), 253 – 260 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chen K , ManK , MetselaarHJ , JanssenHL , PeppelenboschMP , PanQ . Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation . Liver Transpl.20 ( 3 ), 261 – 269 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Langman LJ , JannettoPJ . Individualizing immunosuppressive therapy for transplant patients . Clin. Chem.62 ( 10 ), 1302 – 1303 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• De Mare-Bredemeijer EL , MetselaarHJ . Optimization of the use of calcineurin inhibitors in liver transplantation . Best Pract. Res. Clin. Gastroenterol.26 ( 1 ), 85 – 95 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Christians U , SchmitzV , SchoningWet al. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges . Ther. Drug Monit.30 ( 2 ), 151 – 158 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Christians U , VinksAA , LangmanLJet al. Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs . Ther. Drug Monit.37 ( 6 ), 718 – 724 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Guengerich FP . Human cytochrome P450 enzymes . In : Cytochrome P450 , Springer , Boston, MA, USA , 377 – 530 ( 2005 ).
   Google Scholar
• Rodrigues RM , De KockJ , DoktorovaTY , RogiersV , VanhaeckeT . Measurement of cytochrome P450 enzyme induction and inhibition in human hepatoma cells . Methods Mol. Biol.1250 , 279 – 285 ( 2015 ).
   PubMedGoogle Scholar
• Barbarino JM , StaatzCE , VenkataramananR , KleinTE , AltmanRB . PharmGKB summary: cyclosporine and tacrolimus pathways . Pharmacogenet. Genomics23 ( 10 ), 563 – 585 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Jones SA , MooreLB , ShenkJLet al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution . Mol. Endocrinol.14 ( 1 ), 27 – 39 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Goodwin B , RedinboMR , KliewerSA . Regulation of CYP3A gene transcription by the pregnane x receptor . Annu. Rev. Pharmacol. Toxicol.42 , 1 – 23 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kliewer SA , GoodwinB , WillsonTM . The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism . Endocr. Rev.23 ( 5 ), 687 – 702 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Sommerer C , MeuerS , ZeierM , GieseT . Calcineurin inhibitors and NFAT-regulated gene expression . Clin. Chim. Acta413 ( 17–18 ), 1379 – 1386 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fric J , ZelanteT , WongAY , MertesA , YuHB , Ricciardi-CastagnoliP . NFAT control of innate immunity . Blood120 ( 7 ), 1380 – 1389 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhou Y , YangX , ZhangH , JiangJ . The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats . Transplantation99 ( 6 ), 1126 – 1131 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fischer JaA , HueberAJ , WilsonSet al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis development and characterization of a novel bispecific antibody . Arthritis Rheumatol.67 ( 1 ), 51 – 62 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Liu QL , HuangL , ZhaoQJ , LiQ , HeZ . Relationship between serum interleukin-17 level and inflammatory bowel disease . J. Biol. Regul. Homeost. Agents30 ( 1 ), 181 – 188 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Al-Kufaidy R , Vazquez-TelloA , BahammamAS , Al-MuhsenS , HamidQ , HalwaniR . IL-17 enhances the migration of B cells during asthma by inducing CXCL13 chemokine production in structural lung cells . J. Allergy Clin. Immunol.139 ( 2 ), 696 – 699 e695 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gorbacheva V , FanR , LiX , ValujskikhA . Interleukin-17 promotes early allograft inflammation . Am. J. Pathol.177 ( 3 ), 1265 – 1273 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Chadha R , HeidtS , JonesND , WoodKJ . Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance?Transplantation91 ( 9 ), 939 – 945 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Nordang GB , VikenMK , Hollis-MoffattJEet al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand . Rheumatology (Oxford)48 ( 4 ), 367 – 370 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Arisawa T , TaharaT , ShibataTet al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis . J. Clin. Immunol.28 ( 1 ), 44 – 49 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Espinoza JL , TakamiA , NakataKet al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation . PLoS ONE6 ( 10 ), e26229 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Demetris AJ , BattsKP , DhillonAP et al. Banff schema for grading liver allograft rejection: an international consensus document . Hepatology25 ( 3 ), 658 – 663 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Miossec P , KollsJK . Targeting IL-17 and TH17 cells in chronic inflammation . Nat. Rev. Drug Discov.11 ( 10 ), 763 – 776 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Jones SA , SuttonCE , CuaD , MillsKH . Therapeutic potential of targeting IL-17 . Nat. Immunol.13 ( 11 ), 1022 – 1025 ( 2012 ).
   PubMedGoogle Scholar
• Isailovic N , DaigoK , MantovaniA , SelmiC . Interleukin-17 and innate immunity in infections and chronic inflammation . J. Autoimmun.60 , 1 – 11 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zeng Y , ZhangQ , WangHet al. Prognostic significance of interleukin-17 in solid tumors: a meta-analysis . Int. J. Clin. Exp. Med.8 ( 7 ), 10515 – 10536 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fabrega E , Lopez-HoyosM , San SegundoD , CasafontF , Pons-RomeroF . Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation . Liver Transpl.15 ( 6 ), 629 – 633 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ocejo-Vinyals JG , De MateoEP , HozMAet al. The IL-17 G-152A single nucleotide polymorphism is associated with pulmonary tuberculosis in northern Spain . Cytokine64 ( 1 ), 58 – 61 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Peng R , YueJ , HanM , ZhaoY , LiuL , LiangL . The IL-17F sequence variant is associated with susceptibility to tuberculosis . Gene515 ( 1 ), 229 – 232 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tedesco D , HaragsimL . Cyclosporine: a review . J. Transplant.2012 , 230386 ( 2012 ).
   PubMedGoogle Scholar
• Geissler EK , SchlittHJ . Immunosuppression for liver transplantation . Gut58 ( 3 ), 452 – 463 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Burke JF Jr , PirschJD , RamosELet al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients . N. Engl. J. Med.331 ( 6 ), 358 – 363 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Giese T , ZeierM , MeuerS . Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors . Nephrol. Dial. Transplant.19 ( Suppl. 4 ), iv55 – 60 ( 2004 ).
   PubMedGoogle Scholar
• Krstic J , ObradovicH , KukoljTet al. An overview of interleukin-17A and interleukin-17 receptor A structure, interaction and signaling . Protein Pept. Lett.22 ( 7 ), 570 – 578 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Singh R , SrivastavaA , KapoorR , RKS , RDM . Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of north India . Naunyn Schmiedebergs Arch. Pharmacol.380 ( 2 ), 169 – 177 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Monostory K , TothK , KissAet al. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients . Br. J. Clin. Pharmacol.80 ( 6 ), 1429 – 1437 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Backman JT , FilppulaAM , NiemiM , NeuvonenPJ . Role of cytochrome P450 2C8 in drug metabolism and interactions . Pharmacol. Rev.68 ( 1 ), 168 – 241 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Tracy TS , ChaudhryAS , PrasadBet al. Interindividual variability in cytochrome P450-mediated drug metabolism . Drug Metab. Dispos.44 ( 3 ), 343 – 351 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Nem D , BaranyaiD , QiuH , Godtel-ArmbrustU , NestlerS , WojnowskiL . Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4 . PLoS ONE7 ( 1 ), e30895 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yang J , HaoC , YangDet al. Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes . Toxicol. Lett.197 ( 3 ), 219 – 226 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lee JI , ZhangL , MenAY , KennaLA , HuangSM . CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications . Clin. Pharmacokinet.49 ( 5 ), 295 – 310 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Girish S , MartinSW , PetersonMCet al. AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development . AAPS J.13 ( 3 ), 405 – 416 ( 2011 ).
   PubMedGoogle Scholar
• Evers R , DallasS , DickmannLJet al. Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug–drug interactions and recommendations for best practices: a white paper . Drug Metab. Dispos.41 ( 9 ), 1598 – 1609 ( 2013 ).
   PubMed Web of Science ®Google Scholar